Australia markets closed

CytoDyn Inc. (CYDY)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
1.50000.0000 (0.00%)
At close: 3:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.5000
Open1.5000
Bid0.0000 x 0
Ask0.0000 x 0
Day's range1.5000 - 1.5600
52-week range1.2500 - 7.4000
Volume859,154
Avg. volume2,080,448
Market cap990.288M
Beta (5Y monthly)-0.82
PE ratio (TTM)N/A
EPS (TTM)-0.2550
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    CytoDyn to Hold Webcast and Live Q/A on October 26

    VANCOUVER, Washington, Oct. 21, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer, Scott Kelly, M.D., Chairman, Chief Medical Officer and Head of Business Development, Nitya Ray, Ph.D., Chief Operating Officer and Chief Technology Officer and Christopher R

  • Business Wire

    CytoDyn Announces Delaware Court Has Denied Activist Group’s Motion to Prevent Annual Meeting from Taking Place

    VANCOUVER, Wash., October 20, 2021--CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced the Delaware Court of Chancery has denied a motion by the activist group led by Paul Rosenbaum and Bruce Patterson (the "Activist Group") to prevent the Company’s 2021 Annual Meeting of Stockholders (the "Annual Meeting") from taking place as scheduled on Oc

  • Business Wire

    CytoDyn Alerts Shareholders to Vote on Company’s Proxy Card Ahead of October 28th Annual Meeting

    VANCOUVER, Wash., October 18, 2021--CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that shareholders will receive proxy material beginning this week from the Company in connection with its upcoming 2021 Annual Meeting of Stockholders on October 28, 2021 (the "Annual Meeting").